Carbiotix
Lund
About Carbiotix
Carbiotix is an award winning pre-clinical stage therapeutics company leveraging low-cost gut health testing and microbiome modulators to unlock the potential of the gut microbiome to address a range of chronic and metabolic diseases. Carbiotix was founded in 2014 based on four years of research through the Department of Biotechnology at Lund University and the Antidiabetic Food Centre (AFC) in Lund, Sweden. In 2015, the company’s second-generation soluble fiber AXOS was selected as a top new ingredient by the Nutrition Capital Network (NCN) in Europe and the US. In 2017, Carbiotix began development of its low-cost gut health testing platform and in 2018 launched the platform along with commencing a 600-person gut health study. In 2019, the company began to leverage data from its low-cost gut health testing platform to ramp up therapeutic development activities in line with its long-term strategy to create microbiome modulators based on its proprietary soluble fiber, isolated strains and novel delivery mechanisms.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: sbx:CRBX
- Website: carbiotix.com
Industries & Categories
Biotechnology, Health Care, Personal Health, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/carbiotix-112315 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.